ANALYSIS OF T CELL HYBRIDOMAS
II. Comparisons among Three Distinct Types of Monoclonal Suppressor Factors*

BY KENJI OKUDA, MUTSUHIKO MINAMI, SHUICHI FURUSAWA, AND MARTIN E. DORF

From the Harvard Medical School, Department of Pathology, Boston, Massachusetts 02115

Recent advances in cell hybridization techniques have permitted the fusion of functional T cell subpopulations with tumor cells to yield stable T cell hybridomas (1–9). Such hybrids immortalize the biological activity of an individual cell and permit analysis of monoclonal T cell-derived helper (5) and suppression factors (2, 4, 6, 9, 10). The preparation of monoclonal T cell hybridomas and isolation of biologically active factors derived from monoclonal hybridoma lines can provide a means of dissecting interacting T cell subsets that exist within heterogeneous T cell populations. Such an approach permits a more precise understanding of the mechanism of T cell interactions.

Immune suppression is one such T cell-mediated activity in which multiple T cell populations and soluble factors are required (11). Although initial characterization of the various suppressor T cell populations (Ts)1 has been possible with heterogeneous Ts populations, it remains difficult to analyze the contributions of individual T cell subsets and to insure that a single subset instead of a mixture of subsets is being studied. Furthermore, the quantities of cells or factors obtained from conventional cell preparations are often insufficient for detailed analysis. Thus, the establishment of monoclonal T cell hybrids with specific suppressor function provides an ideal tool for the characterization of the distinct suppressor cell subsets, their products, and their interactions.

Regulation of the immune response to the hapten 4-hydroxy-3-nitrophenyl acetyl (NP) has been extensively characterized (12–16). Previous studies using conventional analysis and monoclonal T cell hybridomas have revealed that in the NP suppressor cell pathway at least three distinct subsets of T cells are required for suppression (13, 14). The first set of Ts, termed Ts1, are induced by antigen, bear idiotypic (Id+) receptors, and can function early in the immune response (10, 12). These Ts1 cells, or a factor produced by these cells, can induce a second set of Ts, termed Ts2 (10, 13,

* Supported by grants CA 14732 and AI 16677 from the National Institutes of Health and grant PCM 80-04573 from the National Science Foundation.

1 Abbreviations used in this paper: C, complement; CGAT, common idiootype on anti-GAT antibodies; CS, cutaneous sensitivity; DMSO, dimethyl sulfoxide; DNFB, 2,4-dinitro-1-fluorobenzene; HBSS, Hanks' balanced salt solution; KLH, keyhole limpet hemocyanin; NP, 4-hydroxy-3-nitrophenyl acetyl hapten; NP-O-Su, NP-O-succinimide ester; PBS, phosphate-buffered saline; RAMG, rabbit anti-mouse immunoglobulin; Ts1, Ts2, Ts3, first-, second-, or third-order suppressor T cells, respectively; TsF1, TsF2, TsF3, suppressor factor derived from Ts1, Ts2, or Ts3 cells, respectively.
The Ts₂ cells bear anti-idiotypic receptors and function late in the immune response (13-15). This Ts₂ cell population or a soluble factor derived from it activates an antigen-primed Ts₃ population that is thought to provide still another suppressor signal (14).

The Ts₃ population was first described by Sy et al. (17) in antigen-primed animals. Further analysis involving the NP system as well as the p-azobenzenearsonate suppressor system has shown that the Ts₃ population possessed idiotypic, Lyt-2, and I-J determinants (14, 18). In addition, the induction of functional Ts₃ cells is sensitive to cyclophosphamide (14, 17). Despite these results, the exact mechanism by which a Ts₃ population manifests immune suppression as well as the nature of the Ts₃-derived factor remained unknown.

To obtain a better understanding of the precise nature and function of Ts₃ cells, we prepared T cell hybridomas that corresponded to the Ts₃ population. In this communication we characterize the biologically active suppressor factors (TsF₃) produced by these hybridoma cells and compare these factors with previously characterized NP-specific TsF₁ and TsF₂ factors.

### Materials and Methods

**Mice.** All mice were either purchased from The Jackson Laboratory, Bar Harbor, Maine, or were bred in the animal facilities at Harvard Medical School, Boston, Mass. Mice were used at 3–12 mo of age and were maintained on laboratory chow and acidified, chlorinated water ad lib.

**Antigens.** NP-O-Succinimide (NP-O-Su) was purchased from Biosearch Co., San Rafael, Calif. Dimethylsulfoxide (DMSO) was purchased from Fisher Scientific Co., Pittsburgh, Pa. 2,4-dinitro-1-fluorobenzene (DNFB) and keyhole limpet hemocyanin (KLH) were obtained from Sigma Chemical Co., St. Louis, Mo.

**Antisera.** Both B10.A(3R) anti-B10.A(5R) (anti-I-Jk) and B10.A(5R) anti-B10.A(3R) (anti-I-Jb) were produced by immunization with spleen and lymph node cells, as described elsewhere (4). Both monoclonal anti-Thy 1.1 and Thy-1.2 antibodies were purchased from New England Nuclear, Boston, Mass. Guinea pig anti-CGAT and anti-NP anti-idiotype antisera were prepared as detailed elsewhere (12, 19). The characterization of these reagents that detect a common idiotype on anti-GAT and anti-NP antibodies, respectively, was described previously (4).

**Preparation of Ts₃ Cells from Antigen Plates.** The methods for the preparation and enrichment of NP-binding T cells were described in detail elsewhere (12). In brief, 5 × 10⁷ regional lymph node or spleen cells from CKB(H₂-k, Igh-Ib) and C57BL/6 (H₂-1, Igh-Iα) mice, which were immunized subcutaneously with 2 mg NP-O-Su or with 100 μg NP-KLH i.p. in Maalox Pertussis (15), were added to purified anti-mouse immunoglobulin (RAMG)-coated petri dishes to remove B cells. The nonadherent T cells were incubated on NP-bovine serum albumin-coated petri dishes for 45 min at room temperature. Nonadherent cells were removed by gentle swirling, and the plates were placed on ice for 20 min. The antigen-binding cells were collected from the plate by gentle pipetting and used as the source of Ts₃ cells.

**Hybridization and Screening of Ts₃ Hybridoma Lines.** Ts₃-enriched CKB or C57BL/6 lymphocytes were hybridized with BW5147 T lymphoma cells. The polyethylene glycol-mediated hybridizing method was exactly the same as previously reported (4). The hybridized Ts₃ candidates were screened using a cytotoxicity test (4) with allele-specific anti-I-J and anti-NP antisera. Three fusions were performed; the CKB-Ts₃-3 and CKB-Ts₃-9 lines were derived from one fusion using CKB NP-O-Su-primed lymph node cells. The B6-Ts₃-2 line was similarly derived from a fusion between NP-O-Su-primed lymph node cells from C57BL/6 mice and BW5147

---

14. Sherr, D. H., and M. E. Dorf. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIII. Characterization of a third-order T cell (Ts₃) involved in suppression of in vitro PFC responses. Manuscript in preparation.
tumor cells. The B6-Ts-19 line was obtained from a third fusion using antigen-adherent splenic T cells from an NP-KLH-primed C57BL/6 mouse. In addition, the B6-Ts-8 hybridoma line was derived from still another fusion in which we were screening for Ts hybrids (Minami and Okuda, unpublished observations). All the Ts hybrids were periodically passaged over the antigen-coated plates, and the idiotype-adherent cells were used to maintain the cell lines. The B6-Ts-2, CKB-Ts-3, and CKB-Ts-9 hybridoma lines were cloned by limiting dilution; 10 of the 11 clones tested had the same phenotype and suppressive activity as the parental line, but one CKB-Ts-3 clone lacked functional activity.

All of the hybridomas were cultured in RPMI 1640 containing 8% fetal calf serum and 0.01 M Hepes buffer. The suppressor factors used in the present experiment were collected from the cultured supernatants of cells at an approximate density of 7 × 10^5 cells/ml in the above medium.

Adsorption and Elution of TsF. The methods of absorption and elution of TsF using protein-conjugated Sepharose-4B columns were described in detail previously (4).

Assay for Suppressive Activity of TsF on NP-mediated Cutaneous Sensitivity (CS) Responses. The assay for NP-specific CS responses was described elsewhere (10, 14). Briefly, each animal was primed subcutaneously with 2 mg of NP-O-Su in DMSO. Unless indicated otherwise, the hybridoma factors were tested in the effector phase, 5 or 6 d after priming. 0.4 ml of each hybridoma supernatant was injected i.v. on the day before and the day of antigen challenge. 6 d after immunization, mice were challenged in the left footpad with 0.025 ml phosphate-buffered saline (PBS) solution containing 30 µg of NP-O-Su (prepared by mixing 25 µl of a 2% NP-O-Su/DSMO solution in 0.4 ml PBS). Footpad swelling was measured 24 h after challenge. Swelling was determined as the difference, in units of 10^-2 cm, between the left and right footpad thickness.

Functional Analysis of TsF and TsFa Factors in Cyclophosphamide-treated Antigen-primed Mice. Mice were primed subcutaneously with NP-O-Su on day 0, as described above. 24 h later, they were treated with an i.p. injection of either saline or 50 mg/kg cyclophosphamide in saline. On days 5 and 6, each mouse received 0.4 ml i.v. of control BW5147 tumor supernatant or Ts2- or Ts3-derived factors. On day 6, mice were challenged with NP-O-Su, and CS responses were measured 24 h later.

DNFB Contact Sensitivity Responses. Contact sensitivity was induced by two daily paintings on the shaved abdomen with 25 µl of 0.5% DNFB solution (Sigma Chemical Co., St. Louis, Mo.) in acetone:olive oil (4:1) (4). 6 d after the last painting, 20 µl of 0.2% DNFB in the same vehicle was applied to the left ear, and the ear swelling was measured as the difference between the left and right ear thicknesses.

Double Antigen Ear Challenge. Individual mice were immunized with either DNFB alone or with DNFB plus NP-O-Su, as described above. Mice were challenged in the left ear by painting with 0.2% DNFB, injecting 0.015 ml containing 6.0 µg NP-O-Su (prepared by mixing 0.025 ml of 0.7% NP-O-Su in DMSO with 0.4 ml PBS, pH 7.7), or with both antigens. The incremental ear swelling was measured 24 and 48 h thereafter. The concentration and volume of NP-O-Su used to challenge was predetermined to elicit high specific ear swelling and low nonspecific backgrounds.

Percent Suppression. The percent suppression in the present study was calculated by the following formula: percent suppression = 100 × [(swelling of BW tumor supernatant-injected group – swelling of TsF-injected group)/(swelling of BW tumor supernatant-injected group – swelling of unprimed group)].

Data Analysis. Statistical analysis of the experimental data with respect to controls was calculated using the two-tailed Student's t test.

Results

Screening of Hybridoma Suppressor Cells. After fusion of antigen-adherent T cells from NP-primed mice with AKR-derived BW5147 tumor cells, 320 of 2,300 wells developed hybridoma colonies. 260 of these 320 lines were screened by the microcytotoxicity test using allele-specific anti-I-J alloantisera. 26% were specifically lysed with anti-I-J alloantisera. 54 of these lines were then screened with guinea pig anti-NPb or control
anti-CGAT-anti-idiotypic antisera; 39% (21 of 54) of these lines were specifically lysed with anti-NPβ idiotypic antisera. Supernatants from those lines that were specifically lysed with both anti-I-J and anti-NPβ were tested for suppressive activity by administering 0.4 ml of supernatant the day before and the day of antigen challenge. At least seven lines demonstrated significant levels of suppressive activity. Five of those that demonstrated >50% suppressive activity of the NP-O-Su CS response were selected for further phenotyping and characterization. The five hybridoma lines that constitutively produced suppressor factor were B6-Ts3-2, B6-Ts3-19, CKB-Ts3-3, and CKB-Ts3-9. Upon retesting, two of the lines (B6-Ts3-8 and B6-Ts3-19) demonstrated variable or no reaction with the anti-I-Jβ or the anti-NPβ idiotypic antisera, although these hybridomas retained their ability to secrete a biologically active suppressor factor (see below). It is not clear why these lines were screened as initially positive, but after continual culture, they appeared to lose their ability to express I-J and idiotypic determinants on their cell surface. Clones of each of these lines were also tested for the presence of I-J and idiotypic determinants, and again the clones appeared to have little or no expression of these antigenic determinants. In contrast, the other three lines have maintained the ability to express cell surface I-J and idiotype determinants.

**Specificity of Suppressor Factors.** To test the biological activity of these presumptive suppressor hybridomas, we screened for the ability of culture supernatants obtained from cells growing at an approximate density of 7 x 10^5 cells/ml to suppress in vivo CS responses. As shown in Table I, injection of 0.4 ml of culture supernatant from the B6-Ts3-2, B6-Ts3-19, and CKB-Ts3-9 cell lines specifically suppressed NP-O-Su-in-

| Source of TsF | Strain tested | TsF dilution | Swelling response (X 10^{-3} cm) ± SE |
|---------------|--------------|--------------|---------------------------------------|
|               |              |              | NP-O-Su (footpad)          | DNFβ (ear)   |
| BW5147        | C57BL/6      | Undiluted    | 27.3 ± 0.9                   | 21.5 ± 0.6  |
| B6-Ts3-2      | C57BL/6      | Undiluted    | 13.0 ± 0.7                   | 22.8 ± 1.7  |
|               |              | 1/10         | 12.8 ± 1.3                   |              |
|               |              | 1/100        | 21.0 ± 1.4                   |              |
|               |              | 1/1000       | 26.3 ± 0.9                   |              |
| B6-Ts3-19     | C57BL/6      | Undiluted    | 15.5 ± 0.6                   | 26.4 ± 2.7  |
|               |              | 1/10         | 14.8 ± 1.1                   |              |
|               |              | 1/100        | 20.8 ± 1.9                   |              |
|               |              | 1/1000       | 27.5 ± 1.1                   |              |
| BW5147        | CKB          | Undiluted    | 25.5 ± 0.5                   | 22.8 ± 2.7  |
| CKB-Ts3-9     | CKB          | Undiluted    | 13.0 ± 1.4                   | 22.0 ± 0.7  |
|               |              | 1/10         | 14.7 ± 0.9                   |              |
|               |              | 1/100        | 25.8 ± 3.6                   |              |
|               |              | 1/1000       | 25.8 ± 1.1                   |              |

* Groups of four to five mice were immunized with either NP-O-Su or DNFβ. The day before and the day of antigen challenge mice were given an i.v. injection of 0.4 ml of either control BW5147 or suppressor factor. The background responses of nonimmunized C57BL/6 mice were 4.1 ± 0.7 and 11.2 ± 1.2 for NP-O-Su and DNFβ, respectively. The background responses of CKB mice were 3.0 ± 0.4 and 2.8 ± 0.7 for NP-O-Su and DNFβ, respectively.

**Significant suppression, P < 0.005.**
duced CS responses. The culture supernatants demonstrated maximum plateau levels of activity when given either undiluted or diluted 1:10. In these experiments the percent of suppression ranged from 50–75%. After further dilution these materials no longer demonstrated significant levels of suppressive activity.

The antigen specificity of these suppressor factors was initially demonstrated by their inability to suppress the DNFB-induced contact sensitivity responses (Table I). The NP specificity of the B6-Ts3-8 and CKB-Ts3-3 suppressor factors was similarly established (data not shown).

Although the specificity of these suppressor factors was demonstrated by the above criteria, it could still be argued that specific antigen is only required to trigger the suppressive activity, and once triggered, the suppression would be nonspecific. Several examples of such antigen-dependent nonspecific suppression have been noted in the literature (22–24). To evaluate the latter possibility, groups of four to five C57BL/6 mice were immunized with either DNFB alone or DNFB plus NP-O-Su. After 5 d, the animals were given either control BW5147 supernatants or culture supernatants from B6-Ts3-2 or B6-Ts3-19 cells. The mice were then challenged in the left ear by painting with DNFB, injecting 7.0 µg NP-O-Su in 15 µl PBS (pH 7.7), or with both antigens. The incremental ear swelling was measured at 24 and 48 h. The data in Table I verify specificity of the B6-Ts3-2 and the B6-Ts3-19 factors. Thus, these latter factors fail to suppress ear swelling responses induced and elicited with DNFB or responses induced with NP-O-Su plus DNFB priming and elicited with DNFB alone. However, the activity of the B6-Ts3-2 and B6-Ts3-19-derived factors was confirmed by their ability to suppress ear swelling responses in mice primed with both NP-O-Su plus DNFB and challenged with NP-O-Su alone. To determine whether these

### Table II

| Antigen priming | TsF source | Antigen challenge | Ear swelling (× 10⁻³ cm) ± SE |
|-----------------|------------|-------------------|-----------------------------|
| DNF B           | BW5147     | DNF B             | 13.0 ± 1.7                  |
| DNF B           | B6-Ts3-2   | DNF B             | 16.0 ± 3.0                  |
| DNF B           | B6-Ts3-19  | DNF B             | 11.0 ± 1.8                  |
|                 | BW5147     | DNF B             | 1.0 ± 0.4                   |
| NP-O-Su + DNF B| BW5147     | DNF B             | 15.0 ± 0.7                  |
| NP-O-Su + DNF B| B6-Ts3-2   | DNF B             | 13.0 ± 1.4                  |
| NP-O-Su + DNF B| B6-Ts3-19  | DNF B             | 16.0 ± 2.7                  |
|                 | BW5147     | DNF B             | 1.0 ± 0.4                   |
| NP-O-Su + DNF B| BW5147     | NP-O-Su           | 18.5 ± 1.2                  |
| NP-O-Su + DNF B| B6-Ts3-2   | NP-O-Su           | 8.3 ± 0.9                   |
| NP-O-Su + DNF B| B6-Ts3-19  | NP-O-Su           | 8.3 ± 2.7                   |
|                 | BW5147     | NP-O-Su           | 8.3 ± 1.9                   |
| DNF B           | BW5147     | NP-O-Su + DNF B   | 16.5 ± 1.2                  |
| DNF B           | B6-Ts3-2   | NP-O-Su + DNF B   | 19.3 ± 2.5                  |
| DNF B           | B6-Ts3-19  | NP-O-Su + DNF B   | 19.0 ± 2.0                  |
|                 | BW5147     | NP-O-Su + DNF B   | 10.5 ± 1.2                  |

* Groups of four to five mice were primed with DNFB alone or with DNFB and NP-O-Su. 5 and 6 d thereafter, they were given TsF or control factors, followed by ear challenge with DNFB, NP-O-Su, or both antigens. The specific ear swelling responses were measured 24 and 48 h after challenge. The data are expressed as the increment of ear swelling (× 10⁻³ cm) ± SE.

† Significant suppression, P < 0.005.
suppressor factors would nonspecifically suppress DNFB responses when the animals were challenged with both NP-O-Su plus DNFB, another series of animals were tested. As shown in Table II, the presence of NP-O-Su in the challenge site is not sufficient to suppress DNFB-induced contact sensitivity responses. Thus, the data demonstrate that these hybridoma-derived suppressor factors are antigen specific.

**Effector-Phase Suppression.** To compare this series of NP-specific suppressor factors with the previously characterized Ts1- and Ts2-derived hybridoma factors, we determined when in the course of the immune response the various factors were active. 0.4 ml of factor was injected i.v. either on the day of and the day after antigen priming (induction phase) or the day before and the day of antigen challenge (effector phase). As previously reported (10), the B6-Ts1-29- and CKB-Ts1-17-derived control TsF1 factors only demonstrated suppressive activity when administered during the induction phase of the immune response (Table III). In contrast, the previously characterized B6-Ts2-28-derived TsF2 factor (20) and the five new hybridoma factors were only active when administered in the effector phase of the NP-O-Su CS response (Table III).

**Genetic Restrictions of Hybridoma Suppressor Factors.** To further compare this new series of hybridoma suppressor factors with those previously characterized, the genetic restrictions of this new series of factors was determined in comparison with the monoclonal control Ts1- and Ts2-derived factors. The Ts1 factor was administered during the induction phase of the immune response, whereas the Ts2 and the new series of suppressor factors were administered during the effector phase. As shown in Table IV and in confirmation of previous data (10, 20), the C57BL/6-derived Ts1 factor from the B6-Ts1-29 cells suppressed NP-specific CS responses in both syngeneic

### Table III

**Comparison of the Ability of TsF to Suppress CS Responses in the Induction vs. Effector Phase**

| TsF source | Strain tested | NP-O-Su primed | NP-O-Su-induced swelling (x 10^-3 cm) ± SE |
|------------|--------------|----------------|------------------------------------------|
|            |              |                | Induction phase | Effector phase |
| None       | C57BL/6      | +              | 36.4 ± 1.4      | 36.5 ± 1.4     |
| B6-Ts1-29  | C57BL/6      | +              | 18.3 ± 1.6      | 35.3 ± 2.9     |
| B6-Ts2-28  | C57BL/6      | +              | 34.9 ± 1.3      | 23.5 ± 1.5     |
| B6-Ts3-2   | C57BL/6      | +              | 39.5 ± 4.2      | 13.8 ± 2.2     |
| B6-Ts3-8   | C57BL/6      | +              | 36.0 ± 5.4      | 21.1 ± 2.1     |
| B6-Ts3-19  | C57BL/6      | +              | 36.8 ± 3.3      | 19.5 ± 3.0     |
| None       | C57BL/6      | -              | 10.6 ± 2.6      | 10.6 ± 2.6     |
| None       | B10.A        | +              | 34.6 ± 3.2      | 34.6 ± 3.6     |
| CKB-Ts1-17 | B10.A        | +              | 12.8 ± 1.8      | 30.4 ± 2.9     |
| CKB-Ts1-3  | B10.A        | +              | 31.5 ± 2.6      | 18.3 ± 1.7     |
| CKB-Ts1-9  | B10.A        | +              | 32.3 ± 1.3      | 16.8 ± 2.0     |
| None       | B10.A        | -              | 8.7 ± 1.2       | 8.7 ± 1.2      |

* Groups of four to five mice were immunized with NP-O-Su and were given TsF either at the time of antigen priming (induction phase) or antigen challenge (effector phase). The results with the control TsF1 and TsF2 factors were obtained from separate experiments. The data were normalized for presentation.

† Significant suppression, *P* < 0.001.
CHARACTERIZATION OF TsF\(^2\) SUPPRESSOR FACTOR

### Table IV

| TsF source | NP-O-Su priming | Footpad swelling (× 10\(^{-3}\) cm) in recipient strains ± SE |
|------------|----------------|---------------------------------------------------------------|
| BW5147     | +              | 24.8 ± 1.9 17.4 ± 1.1 20.8 ± 0.7 31.2 ± 3.1 29.8 ± 2.3 |
| B6-Ts\(_2\)-29 | +               | 10.7 ± 1.3§ 9.7 ± 1.0§ 9.7 ± 1.0 § NT NT |
| B6-Ts\(_2\)-28 | +               | 12.6 ± 1.9 § 16.5 ± 1.9 19.3 ± 0.9 NT NT |
| B6-Ts\(_2\)-2   | +              | 12.2 ± 0.7 § 18.8 ± 0.3 21.5 ± 0.4 12.3 ± 1.9 § 29.5 ± 1.0 |
| B6-Ts\(_2\)-8  | +              | 14.8 ± 1.2 § NT 22.5 ± 2.1 19.5 ± 2.9 § 26.0 ± 1.5 |
| B6-Ts\(_2\)-19 | +              | 9.1 ± 3.1 § NT 25.1 ± 3.4 14.8 ± 2.6 § 32.5 ± 4.2 |
| BW5147     | –              | 3.2 ± 1.0 3.5 ± 1.2 3.5 ± 1.3 6.3 ± 1.3 7.8 ± 1.9 |

* Groups of four to five mice were immunized with NP-O-Su and were given TsF during the induction (TsF\(i\)) or effector phase of the immune response. The data are expressed as the increment of footpad swelling ± SE in units of 10\(^{-3}\) cm.

§ Significant suppression, \(P < 0.05\).

C57BL/6 (H-2\(^b\), Igh\(_b\)) and H-2-incompatible B10.WB (H-2\(^b\), Igh\(_b\)) mice. In contrast, the C57BL/6-derived B6-Ts\(_2\)-28 factor would not suppress NP-specific CS responses in H-2-incompatible B10.WB mice. Furthermore, the Ts\(_2\) factor also failed to suppress CS responses in Igh congenic B6.Igh\(_b\) (H-2\(^b\), Igh\(_b\)) mice. Similarly, the B6-Ts\(_2\)-2, B6-Ts\(_2\)-8, and B6-Ts\(_2\)-19 factors also failed to suppress NP responses in H-2-incompatible B10.WB mice or in Igh-incompatible B6.Igh\(_c\) and C3H.SW (H-2\(^b\), Igh\(_c\)) mice. Because the C57BL/6 and B6.Igh\(_b\) strains as well as the C3H.SW and CWB (H-2\(^b\), Igh\(_b\)) strains are both congenic with respect to the Igh complex, the data suggest that the Ts\(_2\) and the presumed Ts\(_3\)-derived factors are restricted by genes in both the Igh and H-2 complexes. It should be noted that the B6-Ts\(_2\)-2 cells that produced this factor were a cloned subline. In another series of experiments, factors derived from cloned sublines of CKB-Ts\(_3\)-3 and CKB-Ts\(_3\)-9 cells were also shown to be both H-2 and Igh restricted (data not shown). Variations in the magnitude of the NP-specific CS responses in different inbred strains were noted in the data shown in Table IV. This variation appears to correlate with the age of the recipient mice; older animals generally yield larger footpad swelling responses (unpublished observations).

To determine which subregion of the H-2 complex restricted suppressor factor activity, control B6-Ts\(_2\)-28-derived TsF\(_2\), which was previously shown to be I-J\(_b\) restricted (20), and the new series of hybridoma-derived factors were tested in B10.MBR (K\(_b\), I\(_k\), S\(_k\), D\(_b\)), B10.A(3R) (K\(_b\), I\(_A\), I\(_B\), I\(_J\), I\(_E\), I\(_C\), S\(_b\), D\(_b\)), B10.A(4R) (K\(_k\), I\(_A\), I\(_B\), I\(_J\), I\(_C\), S\(_b\), D\(_b\)), and B10.A(5R) (K\(_b\), I\(_A\), I\(_B\), I\(_J\), I\(_E\), I\(_C\), S\(_d\), D\(_d\)) NP-O-Su-primed recipients. The combined results of two independent experiments were normalized and presented in Table V. The C57BL/6 (H-2\(^b\))-derived B6-Ts\(_2\)-28, B6-Ts\(_2\)-2, and B6-Ts\(_2\)-19 factors suppress NP responses in H-2K\(_b\), I-A\(_b\), I-B\(_b\), and I-J\(_b\)-compatible B10.A(3R) and I-B\(_b\), I-J\(_b\), I-E\(_b\), I-C\(_b\), S\(_b\), and H-2D-compatible B10.A(4R) mice but failed to suppress H-2K\(_b\)-compatible B10.MBR or H-2K\(_b\), I-A\(_b\), and I-B\(_b\)-compatible B10.A(5R) recipients. In contrast, the CKB(H-2\(_k\))-derived factors that were derived from cloned CKB-Ts\(_3\)-3 and CKB-Ts\(_3\)-9 sublines suppressed I-A\(_b\), I-B\(_b\), I-J\(_b\), I-E\(_b\), I-C\(_b\), and S-compatible B10.MBR and I-J\(_b\) and I-E-compatible B10.A(5R) recipients but failed to suppress I-E-compatible B10.A(3R) or H-2K\(_b\)- and I-A-com-
TABLE V

Intra-H-2 Mapping of TsF\textsubscript{3} Restriction*

| Source of TsF\textsubscript{3} | NP-O-Su Priming | Footpad swelling (X 10^{-3} cm) in recipient strains ± SE |
|-------------------------------|------------------|--------------------------------------------------------|
|                               |                  | B10.MBR (bkkkkkkc) | B10.A(3R) (bbbkkkdd) | B10.A(4R) (kbbbbbhb) | B10.A(5R) (bbkkkkkk) |
| BW5147 +                     | 36.5 ± 3.6       | 3.8 ± 1.4         | 36.2 ± 2.0           | 31.6 ± 1.6          |
| B6-Ts\textsubscript{2}-28 +   | 39.9 ± 5.2       | 20.6 ± 3.0‡       | 19.3 ± 2.3‡          | 20.8 ± 2.1‡         |
| B6-Ts\textsubscript{2}-19 +   | 34.5 ± 2.1       | 16.8 ± 3.3‡       | 23.0 ± 2.0‡          | 31.0 ± 0.7‡         |
| CKB-Ts\textsubscript{3}-3 +   | 39.6 ± 2.3       | 24.5 ± 3.0‡       | 20.5 ± 3.2‡          | 38.0 ± 4.5          |
| CKB-Ts\textsubscript{3}-9 +   | 21.2 ± 2.6§      | 36.3 ± 1.7        | 32.8 ± 2.1           | 25.0 ± 1.3§         |
| BW5147 -                     | 23.4 ± 2.3§      | 36.5 ± 1.4        | 31.5 ± 2.7           | 21.0 ± 2.5§         |

* Groups of four to five mice were immunized with NP-O-Su and were given TsF during the effector phase of the CS response. The data are expressed as the increment of footpad swelling ± SE in units of 10^{-3} cm. The alleles at the H-2K, IA, I\textbeta, I\textgamma, IE, IC, S, and H-2D regions of the recipient strains are indicated in parentheses. The results with the control TsF\textsubscript{2} factors were obtained from separate experiments, and the data were normalized for presentation.

† Significant suppression, P < 0.005.

TABLE VI

Immunochemical Characterization of Hybridoma Suppressor Factors*

| Immunoabsorbent column | B6-Ts\textsubscript{1}-29 Unbound Eluate | B6-Ts\textsubscript{2}-28 Unbound Eluate | B6-Ts\textsubscript{3}-2 Unbound Eluate | B6-Ts\textsubscript{3}-19 Unbound Eluate | CKB-Ts\textsubscript{3}-9 Unbound Eluate |
|------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| None                   | 83                                     | 5                                      | 67                                     | 65                                     | 69                                     |
| Anti-I\textbeta        | 89                                     | -17                                    | 63                                     | 19                                     | 68                                     |
| Anti-I\textgamma       | 0                                      | 72                                     | 10                                     | 77                                     | -9                                     |
| Anti-NP                | 89                                     | 11                                     | 75                                     | 17                                     | 77                                     |
| NP-KLH                 | 71                                      | 9                                      | 86                                     | 92                                     | 5                                      |

* Hybridoma-derived TsF containing supernatant fluids were adsorbed onto various columns and the unbound and acid-eluted fractions were tested for suppressive activity in either C57B1/6 or B10.BR recipients. The results using the control B6-Ts\textsubscript{1}-29 and B6-Ts\textsubscript{2}-28-derived TsF were previously published (20). The data are expressed as the percent suppression of the NP-O-Su CS response compared with BW5147 supernatant controls. Less than 30% suppression is not significant.

Immunochemical Characterization of Suppressor Factors. In further attempts to distinguish the Ts\textsubscript{2} and the presumed Ts\textsubscript{3}-derived factors from each other and from the previously described TsF\textsubscript{1} factors, selected factors were passed over a series of immunoabsorbent columns. The suppressive activity of the C57BL/6(H-2\textsuperscript{b})-derived factors could be depleted by passage over anti-I\textbeta columns but not anti-I\textgamma columns. In contrast, CKB-Ts\textsubscript{3}-9 (H-2\textsuperscript{K})-derived factor was specifically adsorbed by anti-I\textgamma columns. The suppressive activity could be recovered by acid elution (Table VI). The suppressive activity of the Ts\textsubscript{1}, Ts\textsubscript{2}, and the new series of hybridoma factors was not adsorbed by polyvalent guinea pig anti-immunoglobulin columns that were reactive with \mu, \gamma\textsubscript{1}, \gamma\textsubscript{2a}, \gamma\textsubscript{2b}, \kappa, and \lambda chains. However, the Ts\textsubscript{3} and the new series of hybridoma factors were adsorbed by guinea pig anti-idiotype columns and NP-KLH immunoabsorbent columns. This contrasts the results obtained with B6-Ts\textsubscript{2}-28-derived factor, which could not be adsorbed by either anti-idiotype or NP-KLH immunoabsorbent columns (Table VI and reference 20). However, B6-Ts\textsubscript{2}-28-derived TsF\textsubscript{2} lacks an NP binding site and in...
contrast to the other factors could be depleted on NP<sup>b</sup> idotype columns. The specificity of adsorption was controlled by demonstrating that suppressive activity could be recovered by acid elution from the appropriate columns. Thus, we conclude that this new series of hybridoma factors bear I-J and idiotypic determinants and have a specific receptor for NP hapten. These features distinguish the new series of effector-phase hybridoma-derived suppressor factors from the previously described TsF<sub>2</sub> suppressor factors (20).

**Activity of TsF in Cyclophosphamide-treated Recipients.** Previous reports (14, 17) demonstrated that the precursor T<sub>s3</sub> cells were sensitive to cyclophosphamide treatment. To further compare T<sub>s2</sub>- and T<sub>s3</sub>-derived suppressor factors, hybridoma TsF<sub>2</sub> and TsF<sub>3</sub> were administered to animals that were treated with 50 mg/kg of cyclophosphamide 1 d after antigen priming. The hybridoma-derived suppressor factors were administered during the effector phase of the immune response. As shown in Table VII, cyclophosphamide pretreatment does not alter the magnitude of the NP-specific CS response. Furthermore, B6-Ts<sub>s2</sub>-28-derived factor failed to suppress cyclophosphamide-treated mice, whereas the B6-Ts<sub>s3</sub>-8- and B6-Ts<sub>s3</sub>-19-derived factors were active in cyclophosphamide-treated recipients. Similar results were noted with CKB-derived TsF<sub>2</sub> and TsF<sub>3</sub> factors (data not shown). These results suggest that TsF<sub>2</sub> activates a cyclophosphamide-sensitive T<sub>s3</sub> target population and that TsF<sub>3</sub> can replace the requirement for this cyclophosphamide-sensitive antigen-primed suppressor cell population.

**Discussion**

This report characterizes a new series of suppressor cell hybridoma lines. Five T cell hybridoma lines have been characterized. These new hybridomas differ from the two

**Table VII**

| Experiment number | TsF source | NP-O-Su priming | Cyclophosphamide treatment | Footpad swelling (× 10<sup>-3</sup> cm) ± SE |
|-------------------|------------|-----------------|----------------------------|------------------------------------------|
| 1                 | BW5147     | +               | −                          | 24.0 ± 1.6                               |
|                   | BW5147     | +               | +                          | 23.6 ± 0.7                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | −                          | 12.3 ± 1.4                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | +                          | 23.2 ± 1.6                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | −                          | 10.8 ± 1.9                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | +                          | 10.8 ± 1.1                               |
|                   | B6-Ts<sub>s3</sub>-8 | +   | −                          | 11.0 ± 1.5                               |
|                   | B6-Ts<sub>s3</sub>-8 | +   | +                          | 13.6 ± 1.0                               |
|                   | BW5147     | −               | −                          | 5.8 ± 1.1                                |
| 2                 | BW5147     | +               | −                          | 31.0 ± 1.0                               |
|                   | BW5147     | +               | +                          | 29.3 ± 2.1                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | −                          | 14.8 ± 1.0                               |
|                   | B6-Ts<sub>s2</sub>-28 | +   | +                          | 31.3 ± 1.8                               |
|                   | B6-Ts<sub>s2</sub>-19 | +   | −                          | 18.8 ± 1.4†                               |
|                   | B6-Ts<sub>s2</sub>-19 | +   | +                          | 21.8 ± 1.4†                               |
|                   | None       | −               | −                          | 11.6 ± 1.2†                               |

* Groups of four to five mice were immunized with NP-O-Su, and 24 h later some groups were given 50 mg/kg cyclophosphamide i.p. During the effector phase of the CS response the animals were given 0.4 ml of TsF/d. The data are expressed as the increment of footpad swelling ± SE in units of 10<sup>-3</sup> cm.† Significant suppression, P < 0.001.
other types of NP-specific suppressor T cell hybridoma lines previously characterized (10, 20). First, the cells used for fusion are primarily derived from mice that have been immunized with either NP-O-Su or NP-KLH. In the past, we have used spleen cells from animals that were tolerized by intravenously administering NP-coupled syngeneic cells. However, we obtained one Ts3 hybridoma line from spleen cells of mice that were tolerized with NP-coupled syngeneic cells. Although this demonstrates that Ts3 cells were also present in tolerized animals, the frequency of such cells must be very low. Thus, only one such hybridoma line has been discovered after the screening of several thousand hybridomas from animals that were tolerized with NP-coupled syngeneic cells.

This new series of T cell hybridomas bear allele-specific I-J cell surface determinants and generally bear NPβ-related idiotypic determinants. The presence of Thy-1.2 marker on most of the hybridoma lines and the Lyt-2.2 marker on the B6-Ts3-19 hybridoma (data not shown) is consistent with the previously reported phenotype of the Ts3 population. In a few cases, phenotyping for the Lyt-2.2 marker was not possible because two different monoclonal reagents gave disparate results.

The suppressor factors derived from these hybridoma cell lines were also characterized. The TsF3 suppressor factors differed from the previously characterized TsF1 and TsF2 factors. TsF3 factor acts during the effector phase in contrast to TsF1 factor, which is active only during the induction phase of the CS response. It is not clear why TsF2 or TsF3 factors function only during the effector phase and do not mediate suppression when given during the induction phase of the CS response. One possibility is that these materials have a very short biological half-life. Alternatively, the timing of factor administration with respect to the occurrence of an appropriately differentiated target cell population might be critical.

The antigenic properties of TsF3 were determined by passing these factors over a series of immunoadsorbent columns. TsF- and Ts3-derived factors had similar characteristics. First, both factors bore I-J and NPβ idiotypic determinants and bound to antigen columns; all the suppressor factors lacked constant region immunoglobulin determinants. As reported elsewhere (20), TsF2 factor bound to idiotype columns and apparently possessed an anti-idiotypic receptor (Table VI).

To further distinguish TsF3 factor than TsF1 and TsF2 factors, the genetics of factor activity were analyzed. TsF3 factor, like TsF2 factor, only suppressed strains that were matched at both the IgH and H-2 gene complexes (Table IV). In contrast, TsF1 factor lacks at least H-2 restrictions, but as described elsewhere (10), is pseudo-restricted by genes in the IgH complex. To further distinguish the TsF3 factors from the TsF2 effector-phase factors, the activity of these factors was tested in animals that had been treated with cyclophosphamide. TsF2 factor failed to suppress cyclophosphamide-treated mice, whereas TsF3 factor retained its activity in animals pretreated with cyclophosphamide (Table VII). Finally, the target cells of each type of suppressor factor are distinct. Thus, TsF1 functions by inducing a Ts2 population, whereas Ts3 factor appears to trigger a cyclophosphamide-sensitive Ts3 cell population. The target cell of the TsF3 factor is unknown. Table VIII summarizes the similarities and differences between Ts1, Ts2, and Ts3 cells and the factors derived from these cells.

The literature describes many suppressor cell systems, some of which appear to be antigen specific (24–29), whereas others demonstrate elements of nonspecificity (21–23, 28). The NP system has been shown to be specific in this and in previous reports.
TABLE VIII

Characteristics of NP-specific Suppressor Factors

| Properties of TsF | Phenotype of cell producing TsF | Type of suppressor factor |
|-------------------|---------------------------------|---------------------------|
|                   |                                 | TsF₁ | TsF₂ | TsF₃ |
|                   |                                 | I-J  | I-J  | I-J  |
|                   |                                 | +    | +    | +    |
| I-J               |                                 | +    | +    | +    |
| NP idiotype       |                                 | +    | -    | +    |
| Cell type         |                                 | Tₛ₁  | Tₛ₂  | Tₛ₃  |
| MHC determinants  |                                 | I-J  | I-J  | I-J  |
| Igh-C determinants|                                 | None | None | None |
| Igh-V determinants|                                 | NP   | NP   | NP   |
| Binding specificity|                               | NP   | NP   | NP   |
| Phase of action   |                                 | Induction | Effector | Effector |
| Cellular target   |                                 | Pre-Tₛ₂ | Tₛ₂  | Tₛ₂  |
| Genetic restriction|                               | None | I-J and Igh | I-J and Igh |
| Activity in cyclophosphamide-treated recipients | | ? | None | Yes |

(10, 14, 15). The experiments using animals primed or challenged with DNFB together with NP-O-Su strengthen the conclusion that the suppression mediated in the NP system is antigen specific (Table II). The fact that TsF₃ factor is Igh restricted differs from the observations in some suppressor cell systems (18, 22, 29). There are several possible explanations for these apparently disparate results. First, the systems and the methods used are quite different in the various suppressor models studied. The different methods for evaluating specificity might account for the results observed. It is noteworthy that Fresno et al. (26) have characterized a specific TsF₃-like factor, which upon cleavage or partial degradation becomes antigen nonspecific. We have not evaluated this possibility in our system. An alternative possibility is that there are several Ts₃-like cells, some of which mediate nonspecific suppression. If the latter is true, we must conclude that in the NP system the antigen-specific Igh-restricted Ts₃ population appears to predominate.

The Ts₃ factors show dual genetic restriction, requiring both I-J and Igh region homology for factor activity. Such findings of dual genetic restrictions are not unique to the NP system nor the TsF₃-derived factors. Thus, Suzuki et al. (16) and Dietz et al. (30) have recently also reported dual genetic restrictions of suppressor factors. The fact that Igh restrictions are observed suggests that idiotype-anti-idiotype interactions are required between TsF₃ and its target cells. Furthermore, these Igh restrictions argue against an antigen-bridging mechanism occurring between the TsF₃ and its target cells. The results imply, therefore, that the target of TsF₃ might be an anti-idiotypic suppressor or helper cell population. At the present time, we are attempting to characterize this target population. The I-J restrictions observed with TsF₃ factor might reflect a requirement for an acceptor site on the target cell population that is required for triggering or inactivating the target cell. Alternatively, they might reflect a pseudo-genetic restriction similar to that previously characterized for TsF₁ factors (10).

The Ts₃ cells described in this report constitutively secrete TsF₃ factor. This suggests that some of the Ts₃ cells are normally present in antigen-primed animals. These Ts₃ appear to be fully differentiated and might be involved in the autoregulation of the NP-specific immune response. The question of how these Ts₃ cells are activated
remains unanswered. One possibility is that a few Ts$_2$ cells also exist in antigen-primed mice and these Ts$_2$ cells release TsF$_2$ factor that activates a small percentage of the Ts$_3$ population. Another possibility is that Ts$_3$ cells might also be activated by other means, e.g., anti-idiotype antibody. Finally, we cannot exclude the possibility that in situ the Ts$_3$ cells were not actively secreting TsF$_3$ factor but that after fusion with the BW5147 tumor line the hybrids began to actively secrete TsF$_3$ factor. Preliminary experiments suggest that antigen-primed mice possess a population of mature Ts$_3$ cells that do not secrete TsF$_3$ unless activated with TsF$_2$ factor. This resting Ts$_3$ population presumably accounts for the bulk of the Ts$_3$ cells in antigen-primed mice. Thus, the NP responses of immune animals are not completely suppressed until sufficient Ts$_3$ suppressor cells are activated to regulate the immune response.

The characterization of three distinct series of suppressor factors specific for the CS response to the NP hapten demonstrates the intricacy of the immunoregulatory pathway. The precise differences between the immunoregulatory molecules responsible for the communications between suppressor T cells is unknown. However, the potential availability of large quantities of monoclonal TsF$_1$, TsF$_2$, and TsF$_3$ factors derived from both the C57BL/6 and CKB series of hybridoma lines should permit molecular comparisons among these functionally distinct T cell-derived products.

Summary

Five hybridoma T cell lines were prepared by fusion of Ts$_3$ cells with the BW5147 thymoma. The culture supernatants from these T cell hybrids contained a factor, TsF$_3$, which specifically suppressed 4-hydroxy-3-nitrophenyl acetyl hapten (NP)-hapten cutaneous sensitivity responses. The properties of this new series of hybridoma factors was compared with those of two previously characterized types of NP-specific suppressor factors (TsF$_1$ and TsF$_2$). TsF$_3$ activity was only observed if the factor was administered during the effector phases of the immune response. TsF$_3$ bears I-J and C57BL anti-NP antibody idiotypic determinants and has binding specificity for the NP hapten. Furthermore, TsF$_3$ does not suppress H-2 (I-J)-incompatible mice. In addition to this H-2 restriction, the monoclonal TsF$_3$ factors also demonstrated an Igh genetic restriction. Finally, the TsF$_3$ factors could be distinguished by their ability to suppress cyclophosphamide-treated recipients.

The authors wish to acknowledge the expert secretarial assistance of Mrs. Nancy Axelrod and Mrs. Teresa Dinse. The authors are especially grateful to Dr. Baruj Benacerraf for his support and advice.

Received for publication 24 August 1981.

References

1. Taniguchi, M., and J. F. A. P. Miller. 1978. Specific suppressive factors produced in hybridomas derived from the fusion of enriched suppressor T cells and a T lymphoma cell line. J. Exp. Med. 148:373.
2. Taussig, M., and A. Holliman. 1979. Structure of an antigen-specific suppressor factor produced by a hybrid T cell line. Nature (Lond.). 277:308.
3. Kontiainen, S., E. Simpson, E. Bohrer, P. C. L. Beverly, L. A. Herzenberg, W. C.
CHARACTERIZATION OF TsF$_3$ SUPPRESSOR FACTOR

Fitzpatrick, P. Vogt, A. Torano, I. F. C. McKenzie, and M. Feldmann. 1978. T-cell lines producing antigen-specific suppressor factor. *Nature (Lond.)* 274:477.

4. Okuda, K., M. Minami, S.-T. Ju, and M. E. Dorf. 1981. Functional association of idiotypic and I,J determinants on the antigen receptor of suppressor T cells. *Proc. Natl. Acad. Sci. U. S. A.* In press.

5. Eshhar, Z., R. N. Apte, I. Lowy, Y. Ben-Neriah, D. Givol, and E. Mozes. 1980. T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-spe-
cific helper factor. *Nature (Lond.)* 286:270.

6. Kapp, J. A., B. A. Araneo, and B. L. Clevinger. 1980. Suppression of antibody and T cell proliferative responses to L-glutamic acid$^{60}$-l-alanine$^{80}$-l-tyrosine by a specific monoclonal T cell factor. *J. Exp. Med.* 152:235.

7. Hewitt, J., and F. Y. Liew. 1979. Antigen-specific suppressor factors produced by T cell hybridomas for delayed-type hypersensitivity. *Eur. J. Immunol.* 9:572.

8. Whitaker, R. B., J. T. Nepom, M.-S. Sy, M. Takaoki, C. F. Gramm, I. Fox, R. N. Germain, A. Nisonoff, M. I. Greene, and B. Benacerraf. 1981. Suppressor factor from a T cell hybrid inhibits delayed type hypersensitivity responses to azobenzenearsonate (ABA). *Proc. Natl. Acad. Sci. U. S. A.* In press.

9. Watanabe, T., M. Kimoto, S. Maruyama, T. Kishimoto, and Y. Yamamura. 1978. Regulation of antibody response in different immunoglobulin classes. V. Establishment of T hybrid cell line secreting IgE class-specific suppressor factor. *J. Immunol.* 121:2113.

10. Okuda, K., M. Minami, D. H. Sherr, and M. E. Dorf. 1981. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors. *J. Exp. Med.* 154:468.

11. Germain, R. N., and B. Benacerraf. 1981. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. *Scand. J. Immunol.* 13:1.

12. Weinberger, Z. J., R. N. Germain, S.-T. Ju, M. I. Greene, B. Benacerraf, and M. E. Dorf. 1979. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. II. Demonstration of idiotypic determinants on suppressor T cells. *J. Exp. Med.* 152:161.

13. Sunday, M. E., B. Benacerraf, and M. E. Dorf. 1981. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VIII. Suppressor cell pathways in cutaneous sensitivity responses. *J. Exp. Med.* 153:811.

14. Sherr, D. H., and M. E. Dorf. 1981. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl IX. Characterization of idiotype-specific effector-phase suppressor cells on plaque-forming cell responses in vitro. *J. Exp. Med.* 153:1445.

15. Suzuki, G., Y. Kumagai, Y. Shiratori, H. Karasuyama, T. Kitahara, R. Abe, K. Hayakawa, K. Okumura, and T. Tada. 1980. Expression of NP$^b$ idiotype controlled by genes linked to the Igh-1$^b$ allotype on the NP (4-hydroxy-3-nitrophenyl acetyl) binding T cells. *Proc. Jpn. Soc. Immunol.* 10:121.

16. Sy, M.-S., S. D. Miller, J. W. Moorhead, and H. N. Claman. 1979. Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen. *J. Exp. Med.* 149:1197.

17. Sy, M.-S., A. Nisonoff, R. N. Germain, B. Benacerraf, and M. I. Greene. 1981. Antigen- and receptor-driven regulatory mechanisms. VIII. Suppression of idiotype-negative, p-azobenzenearsonate-specific T cells results from the interaction of an anti-idiotypic second-order T suppressor cell with a cross-reactive idiotype-positive, p-azobenzenearsonate-printed T cell target. *J. Exp. Med.* 153:1415.

18. Ju, S.-T., C. J. Kipps, J. Theze, B. Benacerraf, and M. E. Dorf. 1978. Idiotype analysis of anti-GAT antibodies. I. Presence of common idiotypic specificities in both responder and nonresponder mice. *J. Immunol.* 121:1034.

19. Minami, M., K. Okuda, S. Furusawa, B. Benacerraf, and M. E. Dorf. 1981. Analysis of T
cell hybridomas. I. Characterization of H-2- and Igh-restricted monoclonal suppressor factors. *J. Exp. Med.* In press.

21. Tada, T. 1977. Regulation of the antibody response by T cell products determined by different I subregions. In *The Immune System: Genetics and Regulation*. E. Sercarz, L. A. Herzenberg, and C. F. Fox, editors. Academic Press, Inc., New York. 345–361.

22. Sherr, D. H., K. M. Heghinian, B. Benacerraf, and M. E. Dorf. 1979. Immune suppression in vivo with antigen-modified syngeneic cells. III. Distinctions between T-cell tolerance and T-cell-mediated suppression. *J. Immunol.* 123:2682.

23. Thomas, W. R., F. I. Smith, I. D. Walker, and J. F. A. P. Miller. 1981. Contact sensitivity to azobenzene arsonate and its inhibition after interaction of sensitized cells with antigen-conjugated cells. *J. Exp. Med.* 153:1124.

24. Alevy, Y. G., and C. J. Bellone. 1980. Anti-phenyltrimethylamino immunity in mice. L-tyrosine p-azophenyl-trimethyl-ammonium-induced suppressor T cells selectively inhibit the expression of B-cell clones bearing a cross-reactive idiotype. *J. Exp. Med.* 151:1528.

25. Lynch, R. G., J. W. Rohrer, B. Odermatt, H. W. Gebel, J. R. Autry, and R. G. Hoover. 1979. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. *Immunol. Rev.* 48:45.

26. Fresno, M., L. McVay-Boudreau, G. Nabel, and H. Cantor. 1981. Antigen-specific T lymphocyte clones. II. Purification and biological characterization of an antigen-specific suppressive protein synthesized by cloned T cells. *J. Exp. Med.* 153:1260.

27. Benacerraf, B., J. A. Kapp, P. Debre, C. W. Pierce, and F. Delacroix. 1975. The stimulation of specific suppressor T cells in genetic nonresponder mice by linear random copolymers of L-amino acids. *Transplant. Rev.* 26:21.

28. Rich, S. S., and R. R. Rich. 1976. Regulatory mechanisms in cell-mediated immune responses III. I-region control of suppressor cell interaction with responder cells in mixed lymphocyte reactions. *J. Exp. Med.* 143:672.

29. Chaouat, G., and G. A. Voisin. 1981. Regulatory T cells in pregnancy. V. Allopregnancy-induced T-cell-suppressor factor is H-2 restricted and bears Ia determinants. *Cell. Immunol.* 62:186.

30. Dietz, M. H., M.-S. Sy, B. Benacerraf, A. Nisonoff, M. I. Greene, and R. N. Germain. 1981. Antigen- and receptor-driven regulatory mechanisms. VII. H-2-restricted anti-idiotype suppressor factor from efferent suppressor T cells. *J. Exp. Med.* 153:540.